Weight gain and menstrual abnormalities between users of Depo-provera and Noristerat

Yusuf Abisowo Oshodi, Joy Oyinyechi Agbara, Olamide O. Ade fashola, Fatimat Motunrayo Akinlusi, Haleema Folasade Olalere, Taiwo O. Kuye


Background: Progesterone only injectable contraceptive provides long acting contraception against unwanted pregnancy. Alterations in menstrual pattern are a well known side effect of this effective contraceptive method. Objective of this study was to compare the weight gain and pattern of menstrual abnormalities in users of Depot Medroxyprogesterone Acetate (DMPA) and Norethisterone Enanthate (Noristerat) in LASUTH.

Methods: Retrospective comparative study conducted over a 3year period (January 2013 to December 2015) and involving 237 subjects who used injectable hormonal contraceptive (either DMPA or Noristerat). Case records of all the subjects were retrieved and information obtained on socio-demographic data, parity, previous contraceptive method and reason for discontinuation within one year of usage. Other information including subjects’ weight, menstrual cycle length and pattern, and side effects were collected at 3, 6 and 12 months for DMPA group and 2, 4 and 12 months interval for Noristerat group. Data obtained were analyzed using statistical packages for social sciences (version 19).

Results: The combined mean age was 34.15±1.36 years. The mean weight at commencement was 68.16kg for DMPA and 66.61kg for Noristerat users while after a year, it significantly increased to 71.27kg for DMPA and 69.07kg for Noristerat users (P<0.05). No change in menstrual pattern was noted in 10% of DMPA and 7% of Noristerat users while 60% of DMPA and 57% of Noristerat had amenorrhoea by the end one year period. Five percent each of DMPA and Noristerat users perceived weight gain as problem significant enough to discontinue both methods respectively. Overall, 24% of DMPA and 19.1% of Noristerat users discontinued use after one year.

Conclusions: There were significant weight gain between users of DMPA and Noristerat which was not considered a problem. Amenorrhoea was the commonest menstrual abnormality responsible for discontinuation of either method.


Depo-provera, Menstrual abnormalities, Noristerat, Weight gain

Full Text:



Sedgh G, Bankole A, Oye-Adeniran B, Adewole IF, Singh S, Hussain R. Unwanted pregnancy and associated factors among Nigerian women. International family planning perspectives. 2006:175-84.

Takkar N, Goel P, Saha PK, Dua D. Contraceptive practices and awareness of emergency contraception in educated working women. Ind J Med Sci. 2005;59(4):143-9.

Igwegbe AO, Ugboaja JO. Clinical experience with injectable progestogen only contraceptives at Nnamdi Azikiwe University Teaching Hospital. Nnewi, Nigeria. J Medicine Med Sci. 2010;1(8):345-9.

Sule S, Shittu O. Weight changes in clients on hormonal contraceptives in Zaria, Nigeria. Afri J Rep Health. 2005;9(2):92-100.

Adeyemi AS, Adekanle DA. Progesterone only injectable contraceptive, Experience of women in Osogbo, South Western Nigeria. Dept of O and G Ladoke Akintola University of Tech. Annals Afr. Med. 2012;11(1):27-31.

Hatcher RA, Trussell J, Nelson AL. Contraceptive technology. 20th ed. New York: Ardent Media; 2011.

Adeyemi DA, Adekanle. Progesterone only injectable contraceptive, Experience of women in Osogbo, South Western Nigeria. Dept of O and G Ladoke Akintola University of Tech. Annals of Afr. Med. 2012;11(1):27-31.

Balogun OR, Raji HO. Clinical experience with injectable progestogen-only contraception at university of ilorin teaching hospital: a five-year review. Nigerian Postgraduate Med J. 2009;16:260-3.

Njoku CO, Emechebe CI, Iklaki CU, Njoku AN, Ukaga JT. Progestogen-Only Injectable Contraceptives: The Profile of the Acceptors, Side Effects and Discontinuation in a Low Resource Setting, Nigeria. Open J Obstet Gynecol. 2016;6:189-95.

Konje JC, Oladini F, Otolorin EO, Ladipo OA. Factors determining the choice of contraceptive method at the family planning clinic, University College Hospital, Ibadan. Nig Br J Fam Plan. 1998;24:107-10.

Mutihir JT, Pam VC. Overview of contraceptives use in Jos University Teaching Hospital, North Central Nigeria. Niger J Clin Pract. 2008;11:139-43.

Akadri AA, Odelola OI. Progestogen-only injectable contraceptive: Acceptor prevalence and client experience at Sagamu, Nigeria. Niger Postgrad Med J. 2017;24:178-81.

Ameh N, Sule ST. Contraceptive choices among women in Zaria, Nigeria. Niger J Clin Pract. 2007;10:205-7.

Chigbu B, Onwere S, Aloka C, Kamanu C, Okoro O. Contraceptive choices of women in rural south eastern Nigeria. Niger J Clin Pract. 2010;13:195-9.

Oye Adeniran BA, Adewole IF, Odeyemi KA, Ekenam EE. Contraceptive prevalence among young women in Nigeria. J Obst Gynae. 2005;25(2):182-5.

Moore K, Valdek K, Mc Dougall C, Fink N. Weight Gain and hormonal contraceptives. Contracept. 1995;52(4):215-9.

Mia AR, Siddiqui N, Khan MR, Shampa SS, Rukunuzzaman AN. Effect of prolonged use of injectable hormonal contraceptives on blood pressure and body weight. Mymensingh Med J. 2004;13(1):30-2.

Berenson AB, Rahman M. Changes in weight, total fat, percent body fat, and central-toperipheral fat ratio associated with injectable and oral contraceptive use. Am J Obstet Gynecol. 2009;200(3):329.e1-329.e8.

Ojule JD, Orji VK, Okongwu C. A Five-year review of the complications of progestogen only injectable contraceptive at the University of port-harcourt teaching hospital. Nigerian Journal of Medicine. 2010;19:87-95.

Kaunnitz AM. Long acting hormonal contraception, assessing impact on bone density, weight and mood. Int J Fert W Omen Med. 1999;44(2):110-7.

Kaunnitz AM. Long acting injectable contraception: Depot medroxylprogesterone acetate. Am J Obst Gynae. 1994;170:1543-9.

Polanecky M, Gaernacei M, Alon J. Early experience with contraceptive use of DMPA in an inner city population. Family Planning Perspectives. 1996;174-8.

Chowdhury TA. A clinical study on injectable contraceptive-Noristerat. Bangladesh Med J. 1985;14(2-3):28-35.